References [3] Pmc11486854 [4] Pmc12304053 [5] Pmc12026077 [7] Triple Hormone Therapy Demonstrates Efficacy For Type 2 Diabetes And Obesity [8] Nejmoa2301972 [9] S41591 024 03018 2 [10] Lilly Retatrutide Data Phase Iii Trial All products referenced in this article are intended for research purposes only
The GI symptomsnausea, vomiting, diarrhea, constipation, delayed gastric emptyingare present with both drugs and follow a similar dose-escalation pattern
In China, reported problems increased with age across all items
Screening, Case-Finding, Diagnosis and Monitoring Should a policy of screening for MASLD at risk of fibrotic disease (or fibrosis progression) in primary care or at the non-hepatology specialist level be implemented in the general population or only in individuals with cardiometabolic risk factors
Retatrutide showed a 7% discontinuation rate at the 12mg dose, while Mounjaro demonstrated a 6% discontinuation rate at 15mg
The GLP-1 pill is an alternative to injectable GLP-1 medication